Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LEROY B VAUGHAN

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1366646697
CMS profile
629902
Location
RICHMOND, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$35,628.74

47 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–47 of 47 matching records. This page contains 47 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LEROY B VAUGHAN

NPI 1366646697 · CMS profile ID 629902

Allopathic & Osteopathic Physicians / Internal Medicine

RICHMOND, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–47 of 47 matching records. This page contains 47 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1366646697?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LEROY B VAUGHAN, NPI 1366646697, CMS profile ID 629902. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–47 of 47 matching records. This page contains 47 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366646697?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). LEROY B VAUGHAN, NPI 1366646697, CMS profile ID 629902. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–47 of 47 matching records. This page contains 47 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366646697?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
LEROY B VAUGHAN, NPI 1366646697, CMS profile ID 629902, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–47 of 47 matching records. This page contains 47 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1366646697?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

47 matching records · $35,628.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 47 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–47 of 47.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $7.4212/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274700 CMS
Lilly USA, LLC $13.5812/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135152798 CMS
GENZYME CORPORATION $18.2311/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139755631 CMS
Cumberland Pharmaceuticals, Inc. $16.7610/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146404142 CMS
ABBVIE INC. $17.7010/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274698 CMS
ABBVIE INC. $4,025.0009/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274694 CMS
ABBVIE INC. $2,875.0009/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274696 CMS
ModernaTX, Inc. $30.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560718 CMS
ModernaTX, Inc. $81.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560720 CMS
ModernaTX, Inc. $30.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560722 CMS
ModernaTX, Inc. $45.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560724 CMS
ModernaTX, Inc. $120.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560726 CMS
ABBVIE INC. $124.7409/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274692 CMS
ABBVIE INC. $34.8209/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274688 CMS
ABBVIE INC. $68.3409/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274690 CMS
La Jolla Pharmaceutical Company $25.3307/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154251648 CMS
ABBVIE INC. $4,025.0007/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274686 CMS
ABBVIE INC. $26.1506/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274682 CMS
ABBVIE INC. $2.0406/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274684 CMS
ABBVIE INC. $4,025.0006/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274680 CMS
ABBVIE INC. $122.5306/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274676 CMS
ABBVIE INC. $111.2206/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274678 CMS
ABBVIE INC. $2,875.0006/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274674 CMS
ABBVIE INC. $28.1005/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274668 CMS
ABBVIE INC. $71.5005/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274670 CMS
ABBVIE INC. $330.9805/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274672 CMS
ABBVIE INC. $2,875.0005/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274666 CMS
ABBVIE INC. $120.4605/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274664 CMS
Melinta Therapeutics, LLC $21.9105/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140483472 CMS
ABBVIE INC. $112.7504/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274662 CMS
Melinta Therapeutics, LLC $25.6604/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140485115 CMS
ABBVIE INC. $2,875.0004/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274660 CMS
Paratek Pharmaceuticals, Inc. $15.0404/11/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1113922556 CMS
ABBVIE INC. $4,025.0004/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274658 CMS
ABBVIE INC. $99.3903/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274656 CMS
Ferring Pharmaceuticals Inc. $32.3603/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137516606 CMS
ABBVIE INC. $4.0403/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274654 CMS
ABBVIE INC. $2.5903/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274646 CMS
ABBVIE INC. $125.9003/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274648 CMS
ABBVIE INC. $199.6603/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274650 CMS
ABBVIE INC. $25.0003/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274652 CMS
ABBVIE INC. $3.1903/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274644 CMS
Grifols USA, LLC $26.7502/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124755306 CMS
ABBVIE INC. $2,875.0002/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274642 CMS
ABBVIE INC. $2,875.0002/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274638 CMS
ABBVIE INC. $18.1002/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274640 CMS
ABBVIE INC. $120.5001/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106274636 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $59.09 3
PY2022 $20.46 1
PY2023 $6,049.96 8
PY2024 $35,628.74 47
PY2025 $13,193.85 13

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,807,448.32 336
PY2024 Principal investigator $6,183,192.34 199
PY2023 Recipient $1,340.62 4
PY2023 Principal investigator $9,068,826.97 4,189
PY2022 Principal investigator $2,728,925.31 3,261

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

199 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $36,788.61 12/31/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1130967397
Principal investigator 1 ModernaTX, Inc. $2,066.94 12/30/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131557
Principal investigator 1 ModernaTX, Inc. $4,630.88 12/24/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131555
Principal investigator 1 ModernaTX, Inc. $541,767.98 12/23/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147131549
Principal investigator 1 ModernaTX, Inc. $272.70 12/23/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131553
Principal investigator 1 ModernaTX, Inc. $290,612.13 12/23/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131569
Principal investigator 1 ModernaTX, Inc. $75.13 12/20/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131545
Principal investigator 1 ModernaTX, Inc. $68.30 12/19/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131543
Principal investigator 1 ModernaTX, Inc. $305,709.83 12/19/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131567
Principal investigator 1 PFIZER INC. $43,098.48 12/19/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1130967391
Principal investigator 1 ModernaTX, Inc. $90.90 12/18/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131551
Principal investigator 1 ModernaTX, Inc. $4,878.12 12/16/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147131547
Principal investigator 1 ModernaTX, Inc. $644.80 12/16/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131565
Principal investigator 1 ModernaTX, Inc. $299.34 12/13/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131541
Principal investigator 1 ModernaTX, Inc. $163.92 12/11/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131539
Principal investigator 1 ModernaTX, Inc. $5,000.00 12/09/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131563
Principal investigator 1 PFIZER INC. $40,322.68 12/05/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1130967402
Principal investigator 1 ModernaTX, Inc. $864,466.62 11/27/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147131521
Principal investigator 1 ModernaTX, Inc. $223,570.65 11/27/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131533
Principal investigator 1 PFIZER INC. $46,377.06 11/27/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1130987658
Principal investigator 1 ModernaTX, Inc. $95.62 11/26/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131537
Principal investigator 1 ModernaTX, Inc. $140.00 11/21/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131525
Principal investigator 1 ModernaTX, Inc. $75.13 11/21/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131535
Principal investigator 1 Novavax Inc $14,991.09 11/14/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123377467
Principal investigator 1 ModernaTX, Inc. $367.08 11/13/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131321
Principal investigator 1 ModernaTX, Inc. $440.00 11/13/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131523
Principal investigator 1 ModernaTX, Inc. $8,800.00 11/11/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131531
Principal investigator 1 ModernaTX, Inc. $4,800.00 11/06/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131529
Principal investigator 1 PFIZER INC. $26,163.87 11/05/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1130987664
Principal investigator 1 ModernaTX, Inc. $2,000.00 10/30/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147131491
Principal investigator 1 ModernaTX, Inc. $1,000.00 10/30/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147131493
Principal investigator 1 ModernaTX, Inc. $14,138.28 10/28/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147131485
Principal investigator 1 ModernaTX, Inc. $19,394.44 10/28/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147131487
Principal investigator 1 ModernaTX, Inc. $8,348.60 10/28/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147131489
Principal investigator 1 PFIZER INC. $131,549.06 10/24/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1130995482
Principal investigator 1 ModernaTX, Inc. $367.08 10/23/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131305
Principal investigator 1 ModernaTX, Inc. $10,464.05 10/23/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131499
Principal investigator 1 ModernaTX, Inc. $449.01 10/23/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131517
Principal investigator 1 ModernaTX, Inc. $116.11 10/23/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131519
Principal investigator 1 ModernaTX, Inc. $204.90 10/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131515
Principal investigator 1 ModernaTX, Inc. $7,800.00 10/21/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147131483
Principal investigator 1 ModernaTX, Inc. $1,600.00 10/09/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131497
Principal investigator 1 ModernaTX, Inc. $449.01 10/08/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147131513
Principal investigator 1 ModernaTX, Inc. $550.00 10/07/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131495
Principal investigator 1 ModernaTX, Inc. $399.12 09/30/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131481
Principal investigator 1 ModernaTX, Inc. $2,440.00 09/25/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131473
Principal investigator 1 PFIZER INC. $48,893.72 09/25/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131013081
Principal investigator 1 Novavax Inc $250.00 09/19/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374182
Principal investigator 1 Novavax Inc $650.00 09/19/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374721
Principal investigator 1 Novavax Inc $225.00 09/19/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123377461
Principal investigator 1 Novavax Inc $5,000.00 09/19/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123377463
Principal investigator 1 ModernaTX, Inc. $74,436.84 09/18/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131471
Principal investigator 1 ModernaTX, Inc. $1,000.00 09/12/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131469
Principal investigator 1 ModernaTX, Inc. $1,000.00 09/11/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131467
Principal investigator 1 PFIZER INC. $59,862.59 09/04/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131013075
Principal investigator 1 Novavax Inc $4,000.00 08/29/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123376347
Principal investigator 1 PFIZER INC. $37,278.64 08/27/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131029144
Principal investigator 1 ModernaTX, Inc. $598.68 08/16/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147131465
Principal investigator 1 ModernaTX, Inc. $6,525.00 08/12/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147131459
Principal investigator 1 ModernaTX, Inc. $55,708.53 08/09/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131287
Principal investigator 1 ModernaTX, Inc. $17,373.85 08/09/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131289
Principal investigator 1 Novavax Inc $1,100.00 08/02/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123377465
Principal investigator 1 ModernaTX, Inc. $58,662.36 08/01/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131461
Principal investigator 1 Novavax Inc $90.00 07/25/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375237
Principal investigator 1 Novavax Inc $400.00 07/25/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375239
Principal investigator 1 Novavax Inc $500.00 07/25/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375765
Principal investigator 1 Novavax Inc $93.75 07/25/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375767
Principal investigator 1 Novavax Inc $1,304.26 07/25/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123377459
Principal investigator 1 Novavax Inc $5,476.99 07/18/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374715
Principal investigator 1 PFIZER INC. $8,223.09 07/16/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131044276
Principal investigator 1 PFIZER INC. $777.63 07/11/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131044270
Principal investigator 1 ModernaTX, Inc. $31,318.80 07/01/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147131361
Principal investigator 1 ModernaTX, Inc. $255,119.49 06/28/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131451
Principal investigator 1 PFIZER INC. $11,526.90 06/26/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131067409
Principal investigator 1 Novavax Inc $62,719.75 06/20/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374180
Principal investigator 1 ModernaTX, Inc. $2,269.39 06/06/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131449
Principal investigator 1 PFIZER INC. $330.00 06/06/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131068412
Principal investigator 1 ModernaTX, Inc. $14,600.00 06/05/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131447
Principal investigator 1 ModernaTX, Inc. $2,940.75 05/31/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131439
Principal investigator 1 Novavax Inc $150.00 05/30/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374717
Principal investigator 1 Novavax Inc $937.50 05/30/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374719
Principal investigator 1 Novavax Inc $562.50 05/30/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123376345
Principal investigator 1 ModernaTX, Inc. $138,783.33 05/29/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131437
Principal investigator 1 ModernaTX, Inc. $500.00 05/27/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131435
Principal investigator 1 PFIZER INC. $17,015.90 05/24/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131080678
Principal investigator 1 PFIZER INC. $286,125.75 05/24/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131080738
Principal investigator 1 ModernaTX, Inc. $128,104.66 05/23/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147131425
Principal investigator 1 ModernaTX, Inc. $300.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131133
Principal investigator 1 ModernaTX, Inc. $300.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131135
Principal investigator 1 ModernaTX, Inc. $400.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131137
Principal investigator 1 ModernaTX, Inc. $1,633.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131139
Principal investigator 1 ModernaTX, Inc. $300.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131141
Principal investigator 1 ModernaTX, Inc. $2,024.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131143
Principal investigator 1 ModernaTX, Inc. $5,000.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131145
Principal investigator 1 ModernaTX, Inc. $391.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131147
Principal investigator 1 ModernaTX, Inc. $40.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131149
Principal investigator 1 ModernaTX, Inc. $391.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131151
Principal investigator 1 ModernaTX, Inc. $600.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131153
Principal investigator 1 ModernaTX, Inc. $1,380.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131155
Principal investigator 1 ModernaTX, Inc. $1,400.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131157
Principal investigator 1 ModernaTX, Inc. $736.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131159
Principal investigator 1 ModernaTX, Inc. $600.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131161
Principal investigator 1 ModernaTX, Inc. $900.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131163
Principal investigator 1 ModernaTX, Inc. $880.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131165
Principal investigator 1 ModernaTX, Inc. $300.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131167
Principal investigator 1 ModernaTX, Inc. $300.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131169
Principal investigator 1 ModernaTX, Inc. $7,526.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131171
Principal investigator 1 ModernaTX, Inc. $300.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131173
Principal investigator 1 ModernaTX, Inc. $46.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131175
Principal investigator 1 ModernaTX, Inc. $500.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131177
Principal investigator 1 ModernaTX, Inc. $300.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131179
Principal investigator 1 ModernaTX, Inc. $334.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131181
Principal investigator 1 ModernaTX, Inc. $600.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131183
Principal investigator 1 ModernaTX, Inc. $1,200.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131185
Principal investigator 1 ModernaTX, Inc. $500.00 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131187
Principal investigator 1 ModernaTX, Inc. $9,593.60 05/22/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131433
Principal investigator 1 ModernaTX, Inc. $3,582.48 05/20/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147131423
Principal investigator 1 PFIZER INC. $44,550.00 05/17/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131080744
Principal investigator 1 Novavax Inc $2,531.25 05/16/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375769
Principal investigator 1 Novavax Inc $600.00 05/16/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375771
Principal investigator 1 ModernaTX, Inc. $1,440.00 05/15/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131431
Principal investigator 1 ModernaTX, Inc. $22.80 05/14/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147131421
Principal investigator 1 Novavax Inc $1,500.00 05/09/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374176
Principal investigator 1 Novavax Inc $562.50 05/09/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375241
Principal investigator 1 ModernaTX, Inc. $1,000.00 05/06/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131429
Principal investigator 1 ModernaTX, Inc. $18,300.00 05/03/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147131419
Principal investigator 1 ModernaTX, Inc. $500.00 05/02/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131427
Principal investigator 1 Novavax Inc $5,791.61 05/02/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374178
Principal investigator 1 ModernaTX, Inc. $7,184.10 05/01/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147131417
Principal investigator 1 PFIZER INC. $5,000.00 05/01/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131080732
Principal investigator 1 ModernaTX, Inc. $114,627.51 04/30/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147131407
Principal investigator 1 PFIZER INC. $19,447.00 04/26/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131091386
Principal investigator 1 ModernaTX, Inc. $46,958.40 04/24/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131107
Principal investigator 1 PFIZER INC. $4,000.00 04/24/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131091518
Principal investigator 1 ModernaTX, Inc. $868.39 04/17/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147131405
Principal investigator 1 PFIZER INC. $18,000.00 04/17/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131092587
Principal investigator 1 ModernaTX, Inc. $60.00 04/15/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147131403
Principal investigator 1 PFIZER INC. $334.65 04/12/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131091380
Principal investigator 1 Novavax Inc $128,987.88 04/11/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375235
Principal investigator 1 Novavax Inc $459.30 04/11/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375763
Principal investigator 1 ModernaTX, Inc. $248,607.96 04/10/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131105
Principal investigator 1 PFIZER INC. $2,660.00 04/10/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131090321
Principal investigator 1 PFIZER INC. $12,111.06 04/05/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131092593
Principal investigator 1 PFIZER INC. $12,844.41 04/03/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131091858
Principal investigator 1 PFIZER INC. $16,390.64 03/30/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131100276
Principal investigator 1 PFIZER INC. $6,844.64 03/29/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131100337
Principal investigator 1 ModernaTX, Inc. $52,254.76 03/28/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131395
Principal investigator 1 Novavax Inc $400.00 03/27/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374713
Principal investigator 1 Novavax Inc $400.00 03/27/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123376909
Principal investigator 1 PFIZER INC. $16,862.90 03/26/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131100343
Principal investigator 1 ModernaTX, Inc. $2,525.40 03/21/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147131385
Principal investigator 1 ModernaTX, Inc. $396,921.87 03/21/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131393
Principal investigator 1 ModernaTX, Inc. $7,681.38 03/18/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147131383
Principal investigator 1 ModernaTX, Inc. $15,625.71 03/13/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131391
Principal investigator 1 PFIZER INC. $1,000.00 03/08/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131100331
Principal investigator 1 ModernaTX, Inc. $19,315.62 03/06/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131389
Principal investigator 1 ModernaTX, Inc. $6,238.62 03/04/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131387
Principal investigator 1 ModernaTX, Inc. $739.68 02/28/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147131367
Principal investigator 1 Novavax Inc $400.00 02/27/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123377455
Principal investigator 1 Novavax Inc $75.00 02/27/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123378021
Principal investigator 1 ModernaTX, Inc. $246,127.68 02/26/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131377
Principal investigator 1 PFIZER INC. $45,499.16 02/24/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131100288
Principal investigator 1 ModernaTX, Inc. $165.00 02/23/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131375
Principal investigator 1 ModernaTX, Inc. $500.00 02/21/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131373
Principal investigator 1 Novavax Inc $400.00 02/15/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374711
Principal investigator 1 ModernaTX, Inc. $8,019.18 02/14/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147131365
Principal investigator 1 PFIZER INC. $12,203.92 02/14/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131100282
Principal investigator 1 ModernaTX, Inc. $6,691.10 02/12/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131371
Principal investigator 1 Novavax Inc $25.00 02/08/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374709
Principal investigator 1 Novavax Inc $1,202.07 02/08/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375233
Principal investigator 1 Novavax Inc $400.00 02/08/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375759
Principal investigator 1 Novavax Inc $40.00 02/08/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375761
Principal investigator 1 Novavax Inc $175.00 02/08/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123376343
Principal investigator 1 Novavax Inc $1,725.00 02/08/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123376905
Principal investigator 1 Novavax Inc $400.00 02/08/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123376907
Principal investigator 1 Novavax Inc $400.00 02/08/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123377453
Principal investigator 1 Novavax Inc $22,976.33 02/08/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123377457
Principal investigator 1 Novavax Inc $800.00 02/08/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123378019
Principal investigator 1 ModernaTX, Inc. $720.00 02/02/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131369
Principal investigator 1 ModernaTX, Inc. $3,297.37 01/29/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147131351
Principal investigator 1 ModernaTX, Inc. $2,300.00 01/29/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131357
Principal investigator 1 PFIZER INC. $12,312.16 01/27/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131106547
Principal investigator 1 PFIZER INC. $32,292.84 01/26/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131109779
Principal investigator 1 ModernaTX, Inc. $1,600.00 01/24/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131355
Principal investigator 1 ModernaTX, Inc. $21,979.56 01/19/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147131349
Principal investigator 1 ModernaTX, Inc. $5,119.80 01/18/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147131347
Principal investigator 1 ModernaTX, Inc. $18,084.09 01/16/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131353
Principal investigator 1 ModernaTX, Inc. $84,621.60 01/12/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147131345
Principal investigator 1 ModernaTX, Inc. $600.00 01/10/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131063
Principal investigator 1 ModernaTX, Inc. $2,000.00 01/10/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131065
Principal investigator 1 ModernaTX, Inc. $1,626.00 01/10/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131067
Principal investigator 1 PFIZER INC. $29,169.62 01/09/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131106426
Principal investigator 1 PFIZER INC. $208,966.50 01/04/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131109592
Principal investigator 1 ModernaTX, Inc. $415.00 01/03/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131069
Principal investigator 1 ModernaTX, Inc. $300.00 01/03/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131071
Principal investigator 1 ModernaTX, Inc. $101,658.57 01/03/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131073
Principal investigator 1 ModernaTX, Inc. $415.00 01/03/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147131075
Principal investigator 1 PFIZER INC. $8,532.00 01/03/2024 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130917539
Principal investigator 1 ModernaTX, Inc. $3,967.50 01/02/2024 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147131343